Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 8
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis.
Yu X, Ma H, Li B, Ji Y, Du Y, Liu S, Li Z, Hao Y, Tian S, Zhao C, Du Q, Jin Z, Zhu X, Tian Y, Chen X, Sun X, Yang C, Zhu F, Ju J, Zheng Y, Zhang W, Wang J, Yang T, Wang X, Li J, Xu X, Du S, Lu H, Ma F, Zhang H, Zhang Y, Zhang X, Hu S, He S. Yu X, et al. Blood. 2023 Mar 2;141(9):1070-1086. doi: 10.1182/blood.2022017262. Blood. 2023. PMID: 36356302 Free PMC article.
The Two-Hit Hypothesis Meets Epigenetics.
Issa JP. Issa JP. Cancer Res. 2022 Apr 1;82(7):1167-1169. doi: 10.1158/0008-5472.CAN-22-0405. Cancer Res. 2022. PMID: 35373289 Free PMC article.
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.
O'Connell CL, Baer MR, Ørskov AD, Saini SK, Duong VH, Kropf P, Hansen JW, Tsao-Wei D, Jang HS, Emadi A, Holmberg-Thyden S, Cowland J, Brinker BT, Horwood K, Burgos R, Hostetter G, Youngblood BA, Hadrup SR, Issa JP, Jones P, Baylin SB, Siddiqi I, Grønbaek K. O'Connell CL, et al. Clin Cancer Res. 2022 Dec 15;28(24):5306-5316. doi: 10.1158/1078-0432.CCR-22-1810. Clin Cancer Res. 2022. PMID: 36222848 Free PMC article. Clinical Trial.
Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells.
Pandey S, Djibo R, Darracq A, Calendo G, Zhang H, Henry RA, Andrews AJ, Baylin SB, Madzo J, Najmanovich R, Issa JJ, Raynal NJ. Pandey S, et al. Cancers (Basel). 2022 Jul 8;14(14):3340. doi: 10.3390/cancers14143340. Cancers (Basel). 2022. PMID: 35884401 Free PMC article.
14 results